In a report issued on July 13, Tim Lugo from William Blair maintained a Buy rating on Ovid Therapeutics (OVID). The company’s shares closed last Friday at $7.20.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.0% and a 50.2% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, BioMarin Pharmaceutical, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Ovid Therapeutics is a Strong Buy with an average price target of $13.60, which is an 88.6% upside from current levels. In a report issued on July 13, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $21.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.40 and a one-year low of $1.74. Currently, Ovid Therapeutics has an average volume of 1.41M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
